A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy
- Conditions
- severe novel coronavirus pneumonia (COVID-19)
- Registration Number
- ITMCTR2000003002
- Lead Sponsor
- Huangshi Hospital of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Hospitalized patients with novel coronavirus pneumonia confirmed by pathogenic detection
2. Meet any one of the criteria for severe type:
1) Respiratory distress: RP >= 30/min;
2) At rest, the oxygen saturation <= 93%;
3) Arterial partial pressure of oxygen (PaO2)/Fraction of inspiration (FiO2)(Oxygenation Index, P/F) <= 300mmHg.
3. Aged 18 to 75 years;
4. Signed informed consent.
1. Pregancy or lactating women;
2. People with allergies or allergies to components of Truncated Torsion formula;
3. Patients with serious basic diseases such as malignant tumor, cirrhosis, chronic renal failure (uremic stage), hematological disease, HIV, etc.;
4. Patients with obstructive pneumonia caused by lung tumor, pulmonary fibrosis, alveolar proteinosis and allergic alveolitis;
5. Patients with long-term use of hormone, immunosuppressant and other drugs;
6. Severe mental illness or inability to cooperate with investigators.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 14 day outcome of the subjects, including: recovery, improvement, turning critical, death.;lung CT;
- Secondary Outcome Measures
Name Time Method Routine Blood;APACHE II;oxygenation index;vital signs;major organ function;Coagulation index;inflammatory biomarkers;